​​​​​​​​​​​​Anticoagulation REversal

​​ Latest Research​​

​​​​​​​​​​​​​Fixed-dose four factor PCC​​​FEATURED:
Fixed-dose four-factor PCC for the reversal of Factor Xa Inhibitor-associated bleeding​​​

The purpose of this study is to evaluate the safety and efficacy of fixed-dose 4F-PCC for the management of life-threatening bleeds associated with factor Xa inhibitors.​ Read More >

​​​​​​​Hemostatic Efficacy​​​Novel reversal agents and laboratory evaluation for direct-acting oral anticoagulants (DOAC): an update

Novel oral anticoagulants (NOACs) are no longer “novel” but their reversal agents definitely are. Although NOACs enjoy high clinical efficacy, monitoring and reversal of their effect is a challenge which this review attempts to surmount. ​Read More >​​

​​​​​​​​​​​​​​​CKD​​​Chronic kidney disease and anticoagulation. ​Quick overview and practical g​uide​​​​​​​

Clinicians managing patients with chronic/end-stage renal disease often are challenged when it comes to anticoagulation in this subset.​ Read More >​​

​​​​​​​​​​Hemostatic Efficacy​​​Anticoagulant Reversal in ICH

A 65-year-old man with a history of hypertension, diabetes mellitus, and atrial fibrillation presented with a posterior scalp hematoma and altered mental status after a mechanical fall. The patient's family reported that he was taking apixaban, and his last dose had been four hours before arrival. A physical examination revealed a GCS of 13, a blood pressure of 175/99 mm Hg, and asymmetric pupils.​ Read More >​​​

​​​​​​​​​​​​​​​Reversal of factor XA​​​Andexanet Alfa for reversing Factor Xa Inhibition​

The direct oral anticoagulants (DOACs) have gained popularity recently among both patients and providers for their comparable or better efficacy and safety profiles compared with warfarin and the lack of need for routine monitoring of anticoagulant effect. Read More >​​​

​​​Case Studies​​

​​​​​​Hemostatic Efficacy​​​Hemostatic efficacy and Anti-FXa (Factor Xa) Reversal with Andexanet a​lfa in intracranial hemorrhage: ANNEXA-4 substudy​

​Andexanet alfa is a recombinant modified human FXa (factor Xa) developed to reverse FXa inhibition from anticoagulants. Hemostatic efficacy and reversal of anti-FXa activity with andexanet were assessed in patients from the ANNEXA-4 study (Andexanet Alfa, a Novel Antidote to the Anticoagulation Effects of FXa Inhibitors) with intracranial hemorrhage (ICrH).​ Read More >​​

​​​​​Hemostatic Efficacy​​​Effect of combined therapy with catheter-directed thrombolysis and factor Xa inhibitor for inferior vena cava thrombosis: A case report​

​Inferior vena cava (IVC) thrombosis is an under-recognized entity that is associated with a mortality rate approaching twice that of lower extremity deep venous thrombosis (DVT). Thrombolytic therapy not only results in greater lysis, but also results in higher complication rates than anticoagulation alone.​ ​Read More >​​

​​​​​​Hemostatic Efficacy​​​Successful treatment of amniotic fluid embolism complicated by disseminated intravascular coagulation with rivaroxaban​

An amniotic fluid embolism (AFE) is a rare, lethal syndrome that is commonly associated with disseminated intravascular coagulation (DIC). Anticoagulation therapy is the most important strategy to inhibit excessive activation of the coagulation cascade in patients with AFE and DIC. At present, treatment of AFE with rivaroxaban has not been reported. ​Read More >​​